Charles River Laboratories

CRL

Market cap $8.78B

Contract drug developer Charles River Laboratories raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA and private equity firm GI Partners.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Update on Planned Divestitures.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript

Charles River Laboratories Q4 Review: Approaching A Bottom

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.

Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.

Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and development services from biotech clients.